This AOP is open for adoption and licensed under the BY-SA license. The BY-SA license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

This AOP is open for adoption. Please email to indicate your interest in becoming the main point of contact for this AOP.
AOP: 226


A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

SSRI (Selective serotonin reuptake inhibitor) to hypertension

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
SSRI to hypertension

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool


The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
Lyle Burgoon   (email point of contact)


Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Hsin-Yen Wu
  • Edward Perkins
  • Lyle Burgoon


This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help


Provides users with information concerning how actively the AOP page is being developed, what type of use or input the authors feel comfortable with given the current level of development, and whether it is part of the OECD AOP Development Workplan and has been reviewed and/or endorsed. OECD Status - Tracks the level of review/endorsement the AOP has been subjected to. OECD Project Number - Project number is designated and updated by the OECD. SAAOP Status - Status managed and updated by SAAOP curators. More help
Handbook Version OECD status OECD project
This AOP was last modified on April 29, 2023 16:03

Revision dates for related pages

Page Revision Date/Time
Decreased, intracellular serotonin May 31, 2017 16:47
Decreased, packaged serotonin May 31, 2017 16:46
Decreased, synaptic release May 31, 2017 16:46
Increased, extracellular serotonin May 31, 2017 16:48
Decreased, extracellular serotonin May 31, 2017 16:46
Activation, 5-HT2A (Serotonin 2A) April 13, 2017 15:25
Activate, PLC (Phospholipase C) April 13, 2017 15:26
Increase, inositol triphosphate April 13, 2017 15:27
Increase, intracellular calcium April 13, 2017 15:27
Activate, calmodulin April 13, 2017 15:28
Increase, myosin light chain phosphorylation April 13, 2017 15:29
Increase, vascular smooth muscle contraction April 13, 2017 15:30
Increase, hypertension April 13, 2017 15:30
Decreased, serotonin transporter activity May 31, 2017 16:47
Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin April 14, 2017 14:47
Decreased, intracellular serotonin leads to Decreased, packaged serotonin April 14, 2017 14:47
Decreased, packaged serotonin leads to Decreased, synaptic release April 14, 2017 14:47
Decreased, synaptic release leads to Decreased, extracellular serotonin April 14, 2017 14:48
Decreased, serotonin transporter activity leads to Increased, extracellular serotonin April 14, 2017 14:46
Increased, extracellular serotonin leads to Activation, 5-HT2A June 02, 2017 09:00
Activation, 5-HT2A leads to Activate, PLC April 14, 2017 14:50
Activate, PLC leads to Increase, inositol triphosphate April 14, 2017 14:50
Increase, inositol triphosphate leads to Increase, intracellular calcium April 14, 2017 14:50
Increase, intracellular calcium leads to Activate, calmodulin April 14, 2017 14:51
Activate, calmodulin leads to Increase, myosin light chain phosphorylation April 14, 2017 14:51
Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction April 14, 2017 14:51
Increase, vascular smooth muscle contraction leads to Increase, hypertension April 14, 2017 14:52
SSRI (Selective serotonin reuptake inhibitor) April 13, 2017 15:32


A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

AOP Development Strategy


Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help


Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help


Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 1317 Decreased, serotonin transporter activity Decreased, serotonin transporter activity
KE 1323 Decreased, intracellular serotonin Decreased, intracellular serotonin
KE 1324 Decreased, packaged serotonin Decreased, packaged serotonin
KE 1325 Decreased, synaptic release Decreased, synaptic release
KE 1320 Increased, extracellular serotonin Increased, extracellular serotonin
KE 1347 Decreased, extracellular serotonin Decreased, extracellular serotonin
KE 1336 Activation, 5-HT2A (Serotonin 2A) Activation, 5-HT2A
KE 1337 Activate, PLC (Phospholipase C) Activate, PLC
KE 1338 Increase, inositol triphosphate Increase, inositol triphosphate
KE 1339 Increase, intracellular calcium Increase, intracellular calcium
KE 1340 Activate, calmodulin Activate, calmodulin
KE 1341 Increase, myosin light chain phosphorylation Increase, myosin light chain phosphorylation
KE 1342 Increase, vascular smooth muscle contraction Increase, vascular smooth muscle contraction
AO 1343 Increase, hypertension Increase, hypertension

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help

Sex Applicability

The sex for which the AOP is known to be applicable. More help

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help


List of the literature that was cited for this AOP. More help